Angela Lamarca, Lead of NET HPB and NET Medical Oncologist at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust, shared a post on X:
“CARES009 trial in HCC from ESMO25
Perioperative camrelizumab+rivoceranib vs surgery in resectable HCC (China)
- 93% completed neoadjuvant
- 110 patients received adjuvant
- Surgical complic similar
EFS HR 0.63 (=BIRC)
Benefit accross groups
Major path resp 35.1%.”
Follow the latest ESMO 2025 news on OncoDaily.
